ZOMETA® Patient Case Study and Medical Profile – Diagnosis and Treatment on a Breast Cancer Patient
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA Patient Case Study: Breast Cancer ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Marta N.
  • Aged 57 years
  • Math teacher
  • Grandmother of 2
References
Page  1 2 3

Diagnosis and treatment of bone metastases

  • Marta presented 6 months ago with a 1-month history of pain in the left thigh
  • Bone scan confirmed metastases in the left femur and left ischium
  • No evidence of metastasis to other organs
  • Immediately after her diagnosis, Marta began treatment with
    • — Chemotherapy: docetaxel every 3 weeks + capecitabine BID
    • — Aromatase inhibitor therapy: daily letrozole
    • — ZOMETA® every 3 weeks
  • Marta is currently symptom free




Page  1 2 3